Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Regeneron Pharmaceuticals    REGN

REGENERON PHARMACEUTICALS

(REGN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/15/2021 01/19/2021 01/20/2021 01/21/2021 01/22/2021 Date
517.93(c) 533.89(c) 542.27(c) 535.48(c) 540.79 Last
796 883 995 530 862 666 940 229 137 755 Volume
0.00% +3.08% +1.57% -1.25% +0.99% Change
More quotes
Financials (USD)
Sales 2020 8 545 M - -
Net income 2020 3 178 M - -
Net cash position 2020 5 478 M - -
P/E ratio 2020 19,1x
Yield 2020 -
Sales 2021 10 573 M - -
Net income 2021 3 772 M - -
Net cash position 2021 9 418 M - -
P/E ratio 2021 14,6x
Yield 2021 -
Capitalization 56 517 M 56 517 M -
EV / Sales 2020 5,97x
EV / Sales 2021 4,45x
Nbr of Employees 8 314
Free-Float 83,1%
More Financials
Company
Regeneron Pharmaceuticals specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Sales break down by activity as follows: - sales of products (61.5%); - supply of collaborative services (33.3%): working with Sanofi (54.5% of sales) and Bayer (45.5%); - sales of technology licenses (5.2%). The group also provides subcontracting... 
More about the company
Notations Surperformance© of Regeneron Pharmaceuticals
Trading Rating : Investor Rating :
More Ratings
All news about REGENERON PHARMACEUTICALS
01/21REGENERON PHARMACEUTICALS : Forty of the Nation's Most Talented Young Scientists..
PR
01/21REGENERON PHARMACEUTICALS : Forty of the Nation's Most Talented Young Scientists..
PR
01/21Lilly Antibody Drug Prevents Covid-19 in Nursing Homes, Study Finds
DJ
01/19REGENERON PHARMACEUTICALS : to Report Fourth Quarter and Full Year 2020 Financia..
PR
01/19REGENERON PHARMACEUTICALS : Morgan Stanley Adjusts Regeneron Pharmaceuticals PT ..
MT
01/15REGENERON PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement (fo..
AQ
01/13S&P closes higher with defensive sectors leading gains
RE
01/13Wall St gains steadily while impeachment hearings get underway
RE
01/13SECTOR UPDATE : Health Care Stocks Trading Lower Premarket Wednesday
MT
01/13REGENERON PHARMACEUTICALS : Benchmark Upgrades Regeneron Pharmaceuticals to Buy ..
MT
01/13TIZIANA LIFE SCIENCES : Names Chief Medical Officer
MT
01/13TIZIANA LIFE SCIENCES : Science Appoints New Chief Medial Officer; Shares Up 13%
MT
01/12REGENERON PHARMACEUTICALS : to Supply U.S. Government with up to 1.25 Million Do..
MT
01/12REGENERON PHARMACEUTICALS : U.S. to buy 1.25 mln additional doses of Regeneron's..
RE
01/12REGENERON PHARMACEUTICALS : U.S. government to buy 1.25 mln additional doses of ..
RE
More news
News in other languages on REGENERON PHARMACEUTICALS
01/21ANTIKÖRPER-THERAPIEN GEGEN CORONA : Noch kein Zulassungsprozess in EU
01/13Wall Street ouvre sans tendance claire avant le vote sur l'"impeachment"
01/13Les valeurs à suivre aujourd'hui à Wall Street Mercredi 13 janvier 2020
01/13REGENERON : nouvelle commande américaine d'1,25 million de doses du traitement c..
01/13WALL STREET STOCK EXCHANGE : Les valeurs à suivre à Wall Street
More news
Analyst Recommendations on REGENERON PHARMACEUTICALS
More recommendations
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals Technical Analysis Chart | REGN | US75886F1075 | MarketScreener
Technical analysis trends REGENERON PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 654,96 $
Last Close Price 535,48 $
Spread / Highest target 48,1%
Spread / Average Target 22,3%
Spread / Lowest Target -6,63%
EPS Revisions
Managers and Directors
NameTitle
Leonard S. Schleifer Co-President, Chief Executive Officer & Director
George Damis Yancopoulos Co-President, Director & Chief Scientific Officer
P. Roy Vagelos Chairman
Patrice Gilooly Senior VP-Quality Assurance & Operations
Robert E. Landry Chief Financial Officer & Executive VP-Finance
Sector and Competitors
1st jan.Capitalization (M$)
REGENERON PHARMACEUTICALS10.84%56 517
GILEAD SCIENCES, INC.14.97%83 961
VERTEX PHARMACEUTICALS0.97%62 055
WUXI APPTEC CO., LTD.30.64%60 054
BEIGENE, LTD.38.16%32 552
GENMAB A/S7.19%28 193